Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&JPRD Files Schizophrenia Drugs | Contract Pharma

What are you searching for?

Sign in

J&JPRD Files Schizophrenia Drugs

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted multiple applications to the FDA for the treatment of schizophrenia.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) has submitted multiple applications to the FDA for the treatment of schizophrenia.

The company submitted its response to the FDA complete response letter for paliperidone palmitate, an investigational once-monthly atypical antipsychotic injection. If approved, the drug will be indicated for the acute and maintenance treatment of schizophrenia.

The company also submitted two sNDAs requesting approval for the use of Invega (paliperidone) tablets for the treatment of schizoaffective disorder as monotherapy and for use in combination with antidepressants and/or mood stabilizers. The sNDA submissions include data from two international, six-week double-blind placebo-controlled studies that evaluated the efficacy and safety of Invega in patients with schizoaffective disorder.  

Invega was first approved in the U.S. in December 2006 and is marketed by Janssen. It is approved for the acute and maintenance treatment of schizophrenia in the U.S. and for the treatment of schizophrenia in the E.U. If approved, Janssen will also market paliperidone palmitate.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters